Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
83.10
-3.07 (-3.56%)
At close: Sep 12, 2025, 4:00 PM EDT
83.07
-0.03 (-0.04%)
After-hours: Sep 12, 2025, 7:56 PM EDT
Incyte Revenue
Incyte had revenue of $1.22B in the quarter ending June 30, 2025, with 16.46% growth. This brings the company's revenue in the last twelve months to $4.58B, up 18.87% year-over-year. In the year 2024, Incyte had annual revenue of $4.24B with 14.76% growth.
Revenue (ttm)
$4.58B
Revenue Growth
+18.87%
P/S Ratio
3.50
Revenue / Employee
$1,752,005
Employees
2,617
Market Cap
16.23B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
INCY News
- 4 days ago - Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress - Business Wire
- 5 days ago - Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade. - Barrons
- 5 days ago - Incyte Corporation (INCY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 10 days ago - Incyte Corporation (INCY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript) - Seeking Alpha
- 11 days ago - Incyte Corporation (INCY) Presents At Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 11 days ago - Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa - Business Wire
- 15 days ago - Incyte: Wall Street Underestimates Strength Of Ruxolitinib Portfolio - Seeking Alpha
- 18 days ago - Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire